TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Thymus Transplantation With Immunosuppression

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Transplant Inclusion~* No age limit~* Thyroid studies must be done and if abnormal, must be on therapy~DiGeorge diagnosis - must have 1 symptom from the following list:~* Heart defect~* Hypocalcemia requiring replacement~* 22q11 hemizygosity~* 10p13 hemizygosity~* CHARGE association~* Abnormal ears plus mother with diabetes (type I, type II, or gestational)~Atypical Diagnosis:~* Must have, or have had, a rash. If rash present, biopsy of rash must show T cells in skin. If rash \& adenopathy resolved, must still have oligoclonal T cells.~* Within 1 month of tx must have PHA response \>20 fold above background or \>5,000 cpm, whichever is higher, or response can be \< this.~* Circulating CD3+ T cells \>50/mm3 but CD45RA+CD62L+CD3+ T cells \<50/mm or \<5% of CD3 count, whichever is higher (must be done 2x)~* Immunoscope with \>40% oligoclonal TCRBV families. A 2nd test per sponsor discretion if T cell numbers increase or activation status changes.~* If TREC done pre-tx must have TRECs \<100 per 100,000 CD3+ cells.~Typical Diagnosis:~* Circulating CD3+ CD45RA+ CD62L+ T cells and \<50/mm3 or \<5% of total T cells~* PHA response \>20 fold above background or \>5,000 cpm, whichever is higher.~* 2 studies must show similar immunological findings qualify for this study.~* TRECs, if done, should be \<100/100,000 CD3 cells~Transplant Exclusion:~* Heart surgery \<4 weeks pre-tx date~* Heart surgery anticipated w/in 3 months of proposed tx~* Rejection by surgeon or anesthesiologist as surgical candidates~* Lack of sufficient muscle tissue to accept 0.2 grams/kg transplant

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Thymus Tissue for Transplantation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Effectiveness of Antibiotics for Respiratory Infections

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~We included children between six months and 12 years old, diagnosed with an ARTI (acute otitis media, acute sinusitis, Group A streptococcal \[GAS\] pharyngitis) using International Classification of Diseases diagnosis codes and prescribed an antibiotic. For GAS pharyngitis, the child also had a positive rapid streptococcal test.~Exclusion Criteria:~* Diagnosed with multiple ARTIs~* Diagnosed with another non-ARTI bacterial infection~* Prescribe antibiotics in the past 30 days~* Non-English speaking families~* If GAS pharyngitis diagnosis, age \< 3 years

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Broad-spectrum antibiotics (Type: None): Children diagnosed with an acute respiratory tract infections (ARTI) and prescribed Broad-spectrum antibiotics.
- Narrow-spectrum (Type: None): Children diagnosed with an acute respiratory tract infections (ARTI) and prescribed Narrow-spectrum antibiotics.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Adjuvant Post-radical Cystectomy Treatment for Bladder Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients not more than 70 years old.~* Radical cystectomy performed within 42 days with no microscopic or macroscopic residual after surgery (negative surgical safety margins)~* Having one or more of the risk factors ( P3b,P4a,G3 and /or positive LN)~* ECOG Performance Scale (0-2).~* Adequate liver functions.~* Adequate renal function serum (creatinine \< 1.5 mg).~* No evidence of distant metastasis or other malignancy.~Exclusion Criteria:~* patients who received radiotherapy or chemotherapy prior to radical cystectomy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): post-operative radiotherapy will be done in locally advanced bladder cancer patients (P3b, P4a, G3 and / or LN positive patients) after radical cystectomy Dose of Radiotherapy: 45 Gray Gy/30 fractions/3 weeks
- Arm 2 (Type: EXPERIMENTAL): adjuvant chemotherapy (gemcitabine and cisplatin) in addition to post operative radiotherapy in locally advanced bladder cancer patients (P3b, P4a, G3 and / or LN positive patients) after radical cystectomy
- Arm 3 (Type: EXPERIMENTAL): Adjuvant chemotherapy alone in locally advanced bladder cancer patients (P3b, P4a, G3 and / or LN positive patients) after radical cystectomy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of NNC109-0012 in Subjects With Active Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Czech Republic: Age between 18 - 65 years (both inclusive)~* A diagnosis of RA made at least 3 months prior to trial start~* Active RA~* Methotrexate treatment (between 7.5 mg and 25 mg/week, both inclusive) for at least 12 weeks with a stable dose for at least 4 weeks prior to trial start~* Female subjects must be willing to avoid pregnancy and breast feeding throughout this trial at least until 15 weeks following the last dose of trial medication~* Male subjects with partners of childbearing potential must be willing to use a highly effective contraception throughout trial incl. a 15 week follow up periode~Exclusion Criteria:~* Known or suspected allergy to trial product or related products~* Body Mass Index (BMI) lower than 18.5 or higher than 35.0 kg/m\^2~* Subjects with chronic inflammatory autoimmune disease other than RA (except secondary Sjögren's syndrome or stable hypothyroidism)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: G-CSF and Erythropoetin in Survival of Patients With Decompensated Liver Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients who were known to have cirrhosis of liver with portal hypertension, now decompensated with ascites/ jaundice/ bleed/ HE/ HRS~Exclusion Criteria:~* Age \<12 or \> 75 years~  * Autoimmune disorders~ * HCC~ * Sepsis ( Any culture positive: blood, urine, any other obvious source of infection: UTI, SBP)~ * Multi organ failure~ * Grade 4 HE~ * HIV seropositivity / pregnancy~ * Essential Hypertension~ * Patients being taken up for transplant~ * Refusal to participate in the study

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- G-CSF+EPO (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Early Versus Delayed Artificial Rupture of Membranes (AROM Trial)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥18 years of age~* full term (≥37 weeks) gestations determined by routine obstetrical guidelines~* singleton gestation in cephalic presentation~* Both nulliparous and multiparous women~* Intact membranes~* Bishop score of ≤6 and cervical dilation ≤2cm~Exclusion Criteria:~* Any contraindication to a vaginal delivery or to misoprostol~* fetal demise~* Multifetal gestation~* major fetal anomaly~* prior uterine surgery, previous cesarean section~* women with HIV, hepatitis C, hepatitis B, and women with medical conditions requiring an assisted second stage~* Additional exclusion criteria were as follows: category 3 fetal heart rate tracing, hemolysis elevated liver enzymes and low platelets (HELLP) syndrome or eclampsia, growth restriction \<10th percentile (based on Hadlock growth curves) with reversal of flow in umbilical artery Doppler studies, and growth restriction \<5th percentile with elevated, absent, or reversal of flow in umbilical artery Doppler studies.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Early Amniotomy (Type: ACTIVE_COMPARATOR): Women in the Early AROM group will under amniotomy one hour from Foley Catheter expulsion. Labor augmentation will continue per study protocol. Refer to Appendix A for protocol regimen.
- Delayed Amniotomy (Type: ACTIVE_COMPARATOR): Women in the Delayed AROM group will undergo amniotomy at the discretion of the obstetrician or labor provider. No specific instructions will be given.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Computerized Cognitive Rehabilitation in Ugandan Children With HIV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* HIV children 6 to 16 years of age and enrolled in the CAI program will be eligible should the parent or caregiver consent to participation in the study. They will all be confirmed HIV positive children (ELISA and Western blot). Only children with perinatally acquired HIV infection will be included.~Exclusion Criteria:~* At pre-CCRT medical examination (see medical exam form in appendices) we will exclude children with a medical history of serious birth complications, severe malnutrition, bacterial meningitis, encephalitis, cerebral malaria, or other known brain injury or disorder requiring hospitalization. Also children with seizure or other neurological disability will be excluded. This will be screened using a brief medical history questionnaire and CAI medical chart review.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: t

Study Arms:
- Full Computerized Cognitive Training (Type: EXPERIMENTAL): Intervention is a Computer Cognitive Rehabilitation Training delivered in 24 sessions over 8 weeks (3 times/week). A training session lasts about an hour and consists of 9 training games or programs, 3 pertaining to improving attention, 3 pertaining to improving visual-spatial memory, and 3 pertaining to improving reasoning/planning. Each training game become more difficult as the child gains proficiency.
- Control (Type: NO_INTERVENTION): Passive Control with no intervention training (computer cognitive games) for 8 weeks.
- Limited computerized cognitive training (Type: ACTIVE_COMPARATOR): Intervention is a Computer Cognitive Rehabilitation Training delivered in 24 sessions over 8 weeks (3 times/week). A training session lasts about an hour and consists of 9 training games or programs, 3 pertaining to improving attention, 3 pertaining to improving visual-spatial memory, and 3 pertaining to improving reasoning/planning. In this arm, however, the training games do NOT become progressively more difficult as the child gains proficiency, but rotates randomly among simpler to moderate levels of difficulty for each game. The purpose to to give children int he limited CCRT arm comparable exposure to the cognitive games training as with the full CCRT arm, with the exception of the titrating nature of the game training.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: mHealth for Antenatal Mental Health

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Pregnant women attending antenatal clinics~Exclusion Criteria:~* Diagnosis of any common mental health disorder (i.e., depression or anxiety disorders) as specified in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition~* Receiving treatment for any common mental health disorder~* Recent personal history of any common mental health disorder (i.e., within the past 12 months)~* Not comfortable reading and writing in English~Participants enrolled in the study assessing an app for the monitoring of mood and symptoms of depression need to own an iPhone or any Android-compatible smartphone.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Screening - Scrolling layout (Type: None): Participants will be asked to complete a survey consisting of three sections using an iPad Air tablet:~* Section 1: Demographic information survey~* Section 2: Whooley questions~* Section 3: Edinburgh Postnatal Depression Scale~All questions will be presented on a single screen. This means that participants will have to scroll vertically in order to answer all the questions.
- Screening - Paging layout (Type: None): Participants will be asked to complete a survey consisting of three sections using an iPad Air tablet:~* Section 1: Demographic information survey~* Section 2: Whooley questions~* Section 3: Edinburgh Postnatal Depression Scale~Only one question will be presented at any given time. This means that participants will have to navigate through multiple pages in order to answer all the questions.
- Retrospective plus momentary assessment (Type: None): Participants in this group will be asked to download and install an app onto their own smartphones. After that, they will be asked to complete a sampling protocol consisting of 6 consecutive days, once a month for 6 months. During the 6 assessment days, participants will be required to complete the Edinburgh Postnatal Depression Scale, 5 momentary questions on a 5-point pictorial scale, and 2 contextual questions.
- Retrospective assessment (Type: None): Participants in this group will be asked to download and install an app onto their own smartphones. After that, they will be asked to complete a sampling protocol consisting of one day a month for 6 months. The assessment days will consist of a single administration of the Edinburgh Postnatal Depression Scale.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: VERtebral Fracture Treatment Comparisons in Osteoporotic Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal women with osteoporosis, as defined by low bone mineral density (BMD), i.e. anterior-posterior lumbar spine, total hip or femoral neck BMD ≥1.5 standard deviations below the average BMD for young, healthy, non-Hispanic, Caucasian women~* A minimum of 2 moderate or 1 severe vertebral fragility fractures (confirmed by central reader) were required~Exclusion Criteria:~* Increased risk of osteosarcoma~* History of unresolved skeletal diseases that affect bone metabolism~* History of atypical subtrochanteric or diaphyseal femoral fractures~* Abnormally high or low calcium levels~* Abnormally high parathyroid hormone (PTH) levels~* Severe vitamin D deficiency~* Abnormal thyroid function not corrected by therapy~* History of malignant neoplasms in the last 5 years~* Active liver disease, clinical jaundice~* Significant impairment of hepatic or renal function~* History of nephro- or urolithiasis~* Previous or planned kypho- or vertebroplasty~* Active or risk for osteonecrosis of the jaw~* Active or recent history of upper gastrointestinal disorders~* Unable to stand or sit in the upright position for at least 30 minutes

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Teriparatide (Type: EXPERIMENTAL): Teriparatide 20 microgram (µg) administered by subcutaneous (SC) injection once daily for 24 months.~Placebo given orally once weekly for 24 months.~Elemental Calcium 500 to 1000 milligram per day and Vitamin D 400 to 800 International Units per day, both administered orally once daily while receiving treatment.
- Risedronate (Type: ACTIVE_COMPARATOR): Risedronate 35 milligram (mg) administered orally once weekly for 24 months.~Placebo given by SC injection once daily for 24 months.~Elemental Calcium 500 to 1000 milligram per day and Vitamin D 400 to 800 International Units per day, both administered orally once daily while receiving treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Individualization of Dosage of Irinotecan in the FOLFIRI According to the Genetic Polymorphism of UGT1A1 in the First Line Treatment of Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Colorectal cancer histologically or cytologically proven~* Indication of treatment according to the FOLFIRI + / - bevacizumab or cetuximab or panitumumab~* Age\> 18 years~* Presence of at least one measurable target by RECIST~* Life expectancy\> 3 months~* Satisfactory biological functions (renal, hepatic and hematologic)~* Affiliation to a social security scheme (or be the beneficiary of such a plan) under the terms of the Act of August 9, 2004~* Patient has signed, after informing the informed consent form~Exclusion Criteria:~* Patients of childbearing age and not using effective contraception during treatment and for at least three months after the end of treatment with irinotecan and at least six months after the end of treatment with bevacizumab, cetuximab or panitumumab and patient pregnant or nursing~* Patient with another pathology deemed incompatible with the entry in the protocol~* Prior treatment in metastatic~* Patients taking antiepileptic~* Allergic reaction or intolerance to irinotecan~* Heart failure , kidney , bone marrow , liver or respiratory~* Higher bilirubin 1.5 times the upper limit of normal~* Significant psychiatric or neurological abnormality~* Infectious syndrome requiring treatment with antibiotics or antiviral long-term~* Patients with chronic inflammatory bowel disease and / or bowel obstruction~* Contraindication Association St. John's wort and yellow fever vaccine~* Against Heart indication 5-FU~* Concurrent treatment with a drug test , participation in a clinical trial within \<30 days~* Patient refused to sign the consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- irinotecan dose based on genetic polymorphism of UGT1A1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Chronic Hypnotic Use

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. age 21-70 yrs~2. non-pregnant females who agree to standard birth control for 12 months and males~3. two of the following chronic insomnia complaints: \>30 min sleep latency, \< 6 hrs sleep, or nonrestorative sleep.~4. meet DSM-IV criteria for primary insomnia~Exclusion Criteria:~1. any acute or unstable illness: conditions making it unsafe for the subject to participate, conditions with a potential to disturb sleep (i.e. acute pain, respiratory infection), and conditions which could interact with the pharmacokinetics or pharmacodynamics of zolpidem.~2. chronic illnesses: renal failure, liver disease, seizures, and dementing illnesses.~3. current psychiatric diseases: alcohol or substance abuse, depression, and schizophrenia.~4. a history of alcohol or substance abuse within the past two years.~5. a prestudy positive urine drug screen~6. consuming \>14 standard (1oz) alcoholic drinks per week~7. caffeine consumption \>300 mg/day~8. smoking during the night (11pm-7am).~9. medications including: anxiolytics, hypnotics. both prescription and OTC, (except in the chronic zolpidem group), antidepressants, anticonvulsants, sedating H1 antihistamines (non-sedating second generation H1 antihistamines are allowed), systemic steroids, respiratory stimulants and decongestants, prescription and OTC stimulants, prescription and OTC diet aids, herbal preparations, and narcotic analgesics. All medications and doses will be documented.~10. sleep disordered breathing (SDB) defined as \>10 apnea-hypopneas events per hour of sleep time or any other primary sleep (e.g., restless legs syndrome) or circadian disorder.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Insomniacs (Type: None): Primary insomniacs, ages 21-70, in good general health.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete